// Auto-generated - do not edit
export const substanceName = "Choline_bitartrate";
export const sources = [{"id":"protestkit","fileName":"PROTESTKIT - Choline_bitartrate.json","displayName":"Protest Kit","size":2043},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - Choline_bitartrate.md","displayName":"PsychonautWiki","size":19779},{"id":"wikipedia","fileName":"WIKIPEDIA - Choline_bitartrate.md","displayName":"Wikipedia","size":2806}];
export const contents: Record<string, string> = {
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/Choline_bitartrate",
  "experiencesUrl": "https://www.reddit.com/search/?q=Choline+bitartrate",
  "name": "Choline bitartrate",
  "aliases": [
    "choline"
  ],
  "aliasesStr": "choline",
  "summary": null,
  "reagents": null,
  "classes": {
    "chemical": [
      "Ammonium salt"
    ],
    "psychoactive": [
      "Nootropic"
    ]
  },
  "toxicity": [
    "extremely low toxicity"
  ],
  "addictionPotential": "not habit-forming",
  "tolerance": {
    "full": "after prolonged and repeated usage",
    "half": "7 days",
    "zero": "14 days"
  },
  "crossTolerances": [],
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "50 mg"
        },
        {
          "name": "Light",
          "value": "100 - 250 mg"
        },
        {
          "name": "Common",
          "value": "250 - 1000 mg"
        },
        {
          "name": "Strong",
          "value": "1000 - 2000 mg"
        },
        {
          "name": "Heavy",
          "value": "2000 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.75 - 1.25 hours"
        },
        {
          "name": "Come up",
          "value": "0.25 - 0.5 hours"
        },
        {
          "name": "Peak",
          "value": "2.0 - 4.0 hours"
        },
        {
          "name": "Offset",
          "value": "1.0 - 2.0 hours"
        },
        {
          "name": "Total",
          "value": "4.0 - 8.0 hours"
        },
        {
          "name": "After effects",
          "value": "2.0 - 8.0 hours"
        }
      ],
      "bioavailability": "40%"
    }
  ],
  "interactions": null,
  "effects": "Headache, Dream potentiation, Stimulation, Body odor alteration",
  "categorized_effects": {
    "Physical effects": [
      "Headache",
      "Stimulation",
      "Body odor alteration"
    ],
    "Mental effects": [
      "Dream potentiation"
    ],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "psychonautwiki": `# Choline bitartrate
*Source: https://psychonautwiki.org/wiki/Choline_bitartrate*

## Dosage & Duration

### Oral

**Dosage:**
- Bioavailability: 40%
- Threshold: 50 mg
- Light: 100 - 250 mg
- Common: 250 - 1000 mg
- Strong: 1000 - 2000 mg
- Heavy: 2000 mg +

**Duration:**
- Total: 4 - 8 hours
- Onset: 45 - 75 minutes
- Come up: 15 - 30 minutes
- Peak: 2 - 4 hours
- Offset: 1 - 2 hours
- After effects: 2 - 8 hours

**Choline** is a chemical substance which serves as a precursor to the neurotransmitter [acetylcholine](https://psychonautwiki.org/wiki/Acetylcholine) in the brain. Choline is an essential nutrient in humans, with documented roles in reducing the risk of neural tube defects, fatty liver disease and other pathologies. It is also used in the synthesis of components in cell membranes. Choline is rarely sold as a free base; it is generally combined with an acid to form a salt such as **choline bitartrate** for stability, or conjugated into one of the more complex forms such as [citicoline](https://psychonautwiki.org/wiki/Citicoline) .

Choline supplementation can be used in the treatment of liver disorders, hepatitis, glaucoma, atherosclerosis, Alzheimer's disease, bipolar disorder and possibly other neurological disorders. It has also been shown to have a positive effect on those suffering from alcoholism.

When taken as a supplement, this compound has been reported to produce [nootropic](https://psychonautwiki.org/wiki/Nootropic) effects. It is easily available and commonly sold for this purpose through the use of online supplement vendors.

## Chemistry

Choline is comprised of a quaternary ammonium group and an alcohol functional group, which are connected through an ethyl chain. Its charged cation can bind to a negative group or atom to form various salts, which can produce varying effects. Choline chloridea can form a low-melting deep eutectic solvent mixture with urea with unusual properties. The common choline bitartrate is a white crystalline powder with a melting point of 149-153 °C.

As with other salt forms, not all of the mass of a choline salt is choline. For choline bitartrate, 104.17/253.25 = 41.1% of its mass is the choline cation, the rest being the bitartrate anion. For supplements made to US labelling standards, no conversion is necessary: the amount given is for choline. The field of nutrition, for now, does not apply an analogous conversion to non-salt forms of choline such as the phospholipid forms and Alpha-GPC.

## Pharmacology

Choline and its metabolites are needed for three main physiological purposes:

- Phospholipid synthesis. Choline is required to make various phospholipids, which make up the cell membrane and signaling lipid rafts. Neural lipid rafts are receiving increasing attention in the field of psychiatry.
- Cholinergic neurotransmission, as a precursor to [acetylcholine](https://psychonautwiki.org/wiki/Acetylcholine) synthesis. Supplemental choline may allow acetylcholine to accumulate at higher levels than that which it otherwise would. As acetylcholine is involved in the function of memory, this could potentially account for its [nootropic](https://psychonautwiki.org/wiki/Nootropic) effects. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- Trimethylamine (betaine) production. Trimethylamine is necessary for osmoregulation. It also participates in [SAM-e](https://psychonautwiki.org/wiki/SAM-e) synthesis.

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Stimulation](https://psychonautwiki.org/wiki/Stimulation)** - The stimulation which choline presents can be considered as primarily subtle, less than that of [caffeine](https://psychonautwiki.org/wiki/Caffeine) .
- **[Headaches](https://psychonautwiki.org/wiki/Headaches)**
- **[Body odor alteration](https://psychonautwiki.org/wiki/Body_odor_alteration)** - This occurs in some populations, especially those suffering from trimethylaminuria. Choline is a precursor to trimethylamine, which some persons are not able to easily break down, often resulting in a "fishy smell." ### Cognitive effects
 
- - **[Dream potentiation](https://psychonautwiki.org/wiki/Dream_potentiation)**
### Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) . Additional experience reports can be found here:

- [Erowid Experience Vaults: Choline](https://www.erowid.org/experiences/subs/exp_Vitamins_Choline.shtml)

## Toxicity and harm potential

As choline is a natural precursor to [acetylcholine](https://psychonautwiki.org/wiki/Acetylcholine) which is naturally found in the body, it is well tolerated and therefore unlikely to be harmful in any way. Choline is non-addictive, is not known to cause brain damage, and has an extremely low toxicity relative to dose. Similar to many other [nootropics](https://psychonautwiki.org/wiki/Nootropics) substances, there are relatively few physical side effects associated with acute choline exposure. Various studies have shown that in reasonable doses in a careful context, it presents no negative cognitive, psychiatric or toxic physical consequences of any sort.

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this substance.

### Tolerance and addiction potential

Choline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of choline are built after prolonged and repeated usage. After that, it takes about 7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). Choline presents cross-tolerance with no other known compounds, meaning that after the consumption of choline, other psychoactive compounds will not have a reduced effect.

## Legal status

- **Germany** : Choline bitartrate is an approved dietary supplement.
- **United States** : In the United States, choline is legal as a dietary supplement. The Food and Drug Administration (FDA) requires choline to be in non-dairy infant formula.

## External links

- [Choline (Wikipedia)](https://en.wikipedia.org/wiki/Choline)

## Literature

- Abbott, A. P., Capper, G., Davies, D. L., Rasheed, R. K., & Tambyrajah, V. (2003). Novel solvent properties of choline chloride/urea mixtures. Chemical Communications, 99(1), 70–71. [https://doi.org/10.1039/b210714g](https://doi.org/10.1039/b210714g)
- Behari, J., Yeh, T.-H., Krauland, L., Otruba, W., Cieply, B., Hauth, B., … Monga, S. P. S. (2010). Liver-Specific B-Catenin Knockout Mice Exhibit Defective Bile Acid and Cholesterol Homeostasis and Increased Susceptibility to Diet-Induced Steatohepatitis. The American Journal of Pathology, 176(2), 744–753. [https://doi.org/10.2353/ajpath.2010.090667](https://doi.org/10.2353/ajpath.2010.090667)
- Chan, K. C., So, K. fai, & Wu, E. X. (2009). Proton magnetic resonance spectroscopy revealed choline reduction in the visual cortex in an experimental model of chronic glaucoma. Experimental Eye Research, 88(1), 65–70. [https://doi.org/10.1016/j.exer.2008.10.002](https://doi.org/10.1016/j.exer.2008.10.002)
- Doggrell, S. a, & Evans, S. (2003). Treatment of dementia with neurotransmission modulation. Expert Opinion on Investigational Drugs, 12(10), 1633–54. [https://doi.org/10.1517/13543784.12.10.1633](https://doi.org/10.1517/13543784.12.10.1633)
- Glier, M. B., Green, T. J., & Devlin, A. M. (2014). Methyl nutrients, DNA methylation, and cardiovascular disease. Molecular Nutrition and Food Research, 58(1), 172–182. [https://doi.org/10.1002/mnfr.201200636](https://doi.org/10.1002/mnfr.201200636)
- Klatskin, G. (1954). the Effect of Alcohol on the Choline Requirement: Ii. Incidence of Renal Necrosis in Weanling Rats Following Short Term Ingestion of Alcohol. Journal of Experimental Medicine, 100(6), 615–627. [https://doi.org/10.1084/jem.100.6.615](https://doi.org/10.1084/jem.100.6.615)
- Nery, F. G., Stanley, J. A., Chen, H.-H., Hatch, J. P., Nicoletti, M. A., Serap Monkul, E., … Soares, J. C. (2010). Bipolar disorder comorbid with alcoholism: A 1H magnetic resonance spectroscopy study. Journal of Psychiatric Research, 44(5), 278–285. [https://doi.org/10.1016/j.jpsychires.2009.09.006](https://doi.org/10.1016/j.jpsychires.2009.09.006)
- Parnetti, L., Mignini, F., Tomassoni, D., Traini, E., & Amenta, F. (2007). Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation? Journal of the Neurological Sciences, 257(1–2), 264–269. [https://doi.org/10.1016/j.jns.2007.01.043](https://doi.org/10.1016/j.jns.2007.01.043)
- Stoll, A. L., Sachs, G. S., Cohen, B. M., Lafer, B., Christensen, J. D., & Renshaw, P. F. (1996). Choline in the treatment of rapid-cycling bipolar disorder: Clinical and neurochemical findings in lithium-treated patients. Biological Psychiatry, 40(5), 382–388. [https://doi.org/10.1016/0006-3223(95)00423-8](https://doi.org/10.1016/0006-3223(95)00423-8)
- Tolvanen, T., Yli-Kerttula, T., Ujula, T., Autio, A., Lehikoinen, P., Minn, H., & Roivainen, A. (2010). Biodistribution and radiation dosimetry of [11C]choline: A comparison between rat and human data. European Journal of Nuclear Medicine and Molecular Imaging, 37(5), 874–883. [https://doi.org/10.1007/s00259-009-1346-z](https://doi.org/10.1007/s00259-009-1346-z)
- Van Beek, A. H. E. A., & Claassen, J. A. H. R. (2011). The cerebrovascular role of the cholinergic neural system in Alzheimer’s disease. Behavioural Brain Research, 221(2), 537–542. [https://doi.org/10.1016/j.bbr.2009.12.047](https://doi.org/10.1016/j.bbr.2009.12.047)
- Zeisel, S. H., & Da Costa, K. A. (2009). Choline: An essential nutrient for public health. Nutrition Reviews, 67(11), 615–623. [https://doi.org/10.1111/j.1753-4887.2009.00246.x](https://doi.org/10.1111/j.1753-4887.2009.00246.x)

## References
1. ↑ 1.0 1.1 Zeisel, S. H., Costa, K.-A. da (November 2009).["Choline: an essential nutrient for public health"](https://academic.oup.com/nutritionreviews/article-lookup/doi/10.1111/j.1753-4887.2009.00246.x).*Nutrition Reviews*.**67**(11): 615–623.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/j.1753-4887.2009.00246.x](//doi.org/10.1111%2Fj.1753-4887.2009.00246.x).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0029-6643](//www.worldcat.org/issn/0029-6643).
2. ↑ 2.0 2.1 2.2 Glier, M. B., Green, T. J., Devlin, A. M. (January 2014).["Methyl nutrients, DNA methylation, and cardiovascular disease"](https://onlinelibrary.wiley.com/doi/10.1002/mnfr.201200636).*Molecular Nutrition & Food Research*.**58**(1): 172–182.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/mnfr.201200636](//doi.org/10.1002%2Fmnfr.201200636).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1613-4125](//www.worldcat.org/issn/1613-4125).
3. ↑ Tolvanen, T., Yli-Kerttula, T., Ujula, T., Autio, A., Lehikoinen, P., Minn, H., Roivainen, A. (May 2010).["Biodistribution and radiation dosimetry of [11C]choline: a comparison between rat and human data"](http://link.springer.com/10.1007/s00259-009-1346-z).*European Journal of Nuclear Medicine and Molecular Imaging*.**37**(5): 874–883.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/s00259-009-1346-z](//doi.org/10.1007%2Fs00259-009-1346-z).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1619-7070](//www.worldcat.org/issn/1619-7070).
4. ↑ Behari, J., Yeh, T.-H., Krauland, L., Otruba, W., Cieply, B., Hauth, B., Apte, U., Wu, T., Evans, R., Monga, S. P. S. (February 2010).["Liver-Specific β-Catenin Knockout Mice Exhibit Defective Bile Acid and Cholesterol Homeostasis and Increased Susceptibility to Diet-Induced Steatohepatitis"](https://linkinghub.elsevier.com/retrieve/pii/S0002944010603884).*The American Journal of Pathology*.**176**(2): 744–753.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2353/ajpath.2010.090667](//doi.org/10.2353%2Fajpath.2010.090667).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0002-9440](//www.worldcat.org/issn/0002-9440).
5. ↑ Chan, K. C., So, K., Wu, E. X. (January 2009).["Proton magnetic resonance spectroscopy revealed choline reduction in the visual cortex in an experimental model of chronic glaucoma"](https://linkinghub.elsevier.com/retrieve/pii/S0014483508003333).*Experimental Eye Research*.**88**(1): 65–70.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.exer.2008.10.002](//doi.org/10.1016%2Fj.exer.2008.10.002).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0014-4835](//www.worldcat.org/issn/0014-4835).
6. ↑ Van Beek, A. H. E. A., Claassen, J. A. H. R. (August 2011).["The cerebrovascular role of the cholinergic neural system in Alzheimer's disease"](https://linkinghub.elsevier.com/retrieve/pii/S016643281000015X).*Behavioural Brain Research*.**221**(2): 537–542.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.bbr.2009.12.047](//doi.org/10.1016%2Fj.bbr.2009.12.047).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0166-4328](//www.worldcat.org/issn/0166-4328).
7. ↑ Stoll, A. L., Sachs, G. S., Cohen, B. M., Lafer, B., Christensen, J. D., Renshaw, P. F. (September 1996).["Choline in the treatment of rapid-cycling bipolar disorder: Clinical and neurochemical findings in lithium-treated patients"](https://linkinghub.elsevier.com/retrieve/pii/0006322395004238).*Biological Psychiatry*.**40**(5): 382–388.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0006-3223(95)00423-8](//doi.org/10.1016%2F0006-3223%2895%2900423-8).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0006-3223](//www.worldcat.org/issn/0006-3223).
8. ↑ Klatskin, G., Krehl, W. A. (1 December 1954).["THE EFFECT OF ALCOHOL ON THE CHOLINE REQUIREMENT"](https://rupress.org/jem/article/100/6/615/2074/THE-EFFECT-OF-ALCOHOL-ON-THE-CHOLINE-REQUIREMENT).*Journal of Experimental Medicine*.**100**(6): 615–627.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1084/jem.100.6.615](//doi.org/10.1084%2Fjem.100.6.615).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1540-9538](//www.worldcat.org/issn/1540-9538).
9. ↑ Nery, F. G., Stanley, J. A., Chen, H.-H., Hatch, J. P., Nicoletti, M. A., Serap Monkul, E., Lafer, B., Soares, J. C. (April 2010).["Bipolar disorder comorbid with alcoholism: A 1H magnetic resonance spectroscopy study"](https://linkinghub.elsevier.com/retrieve/pii/S0022395609002064).*Journal of Psychiatric Research*.**44**(5): 278–285.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.jpsychires.2009.09.006](//doi.org/10.1016%2Fj.jpsychires.2009.09.006).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0022-3956](//www.worldcat.org/issn/0022-3956).
10. ↑ Abbott, A. P., Capper, G., Davies, D. L., Rasheed, R. K., Tambyrajah, V. (19 December 2003).["Novel solvent properties of choline chloride/urea mixturesElectronic supplementary information (ESI) available: spectroscopic data"](http://xlink.rsc.org/?DOI=b210714g).*Chemical Communications*(1): 70–71.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1039/b210714g](//doi.org/10.1039%2Fb210714g).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1359-7345](//www.worldcat.org/issn/1359-7345).
11. ↑ ["Choline bitartrate"](https://pubchem.ncbi.nlm.nih.gov/compound/Choline-bitartrate). Text " C9H19NO7" ignored ( [help](/w/index.php?title=Help:CS1_errors&action=edit&redlink=1) ); Unknown parameter |site= ignored ( [help](/w/index.php?title=Help:CS1_errors&action=edit&redlink=1) )
12. ↑ ["USDA Database for the Choline Content of Common Foods, Release 2"](https://data.nal.usda.gov/dataset/usda-database-choline-content-common-foods-release-2-2008).*USDA Ag Data Commons*(in English). January 2008.Total choline content was calculated as the sum of Cho, GPC, Pcho, Ptdcho, and SM.
13. ↑ Rucker RB, Zempleni J, Suttie JW, McCormick DB (2007).[Handbook of vitamins](https://archive.org/details/handbookvitamins00jzem)(4th ed.). Taylor & Francis. pp.[459](https://archive.org/details/handbookvitamins00jzem/page/n471)–477.[ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number)[9780849340222](http://en.wikipedia.org/wiki/Special:BookSources/9780849340222).
14. ↑ Wray, Nathan H.; Rasenick, Mark M. (2019). "Lipid rafts in psychiatry".*Advances in Pharmacology*.**86**: 21–45.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/bs.apha.2019.04.001](//doi.org/10.1016%2Fbs.apha.2019.04.001).
15. ↑ Kashyap, A. S. (1 May 2000).["Fish odour syndrome"](https://pmj.bmj.com/lookup/doi/10.1136/pmj.76.895.318a).*Postgraduate Medical Journal*.**76**(895): 318a–3318.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1136/pmj.76.895.318a](//doi.org/10.1136%2Fpmj.76.895.318a).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0032-5473](//www.worldcat.org/issn/0032-5473).
16. ↑ BVL 2018/01/004 | [https://www.bvl.bund.de/DE/Arbeitsbereiche/01_Lebensmittel/04_AntragstellerUnternehmen/07_Allgemeinverfuegungen/01_Archiv_Uebersicht/07_Nahrungsergaenzungsmittel/lm_AV_BVL-18-01-004.pdf?__blob=publicationFile&v=3](https://www.bvl.bund.de/DE/Arbeitsbereiche/01_Lebensmittel/04_AntragstellerUnternehmen/07_Allgemeinverfuegungen/01_Archiv_Uebersicht/07_Nahrungsergaenzungsmittel/lm_AV_BVL-18-01-004.pdf?__blob=publicationFile&v=3)
17. ↑ United States Government Publishing Office (2017) [https://www.ecfr.gov/cgi-bin/text-idx?SID=10e89c74892c74350b79d3a4e51b1338&mc=true&node=se21.2.107_1100&rgn=div8](https://www.ecfr.gov/cgi-bin/text-idx?SID=10e89c74892c74350b79d3a4e51b1338&mc=true&node=se21.2.107_1100&rgn=div8)NewPP limit report Cached time: 20251218075247 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.03 seconds CPU time usage: 0.298 seconds Real time usage: 0.669 seconds Preprocessor visited node count: 1553/1000000 Post‐expand include size: 82149/2097152 bytes Template argument size: 3567/2097152 bytes Highest expansion depth: 12/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 25807/5000000 bytes Lua time usage: 0.290/7 seconds Lua virtual size: 8.31 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 567.857 1 -total 54.26% 308.109 12 Template:Cite_journal 17.00% 96.556 1 Template:Citation_needed 11.28% 64.040 1 Template:Fix 10.60% 60.192 2 Template:Category_handler 8.68% 49.301 1 Template:SubstanceBox/Choline_bitartrate 8.17% 46.405 1 Template:SubstanceBox 5.31% 30.175 2 Template:Cite_web 4.74% 26.910 1 Template:Effects/base 4.04% 22.914 1 Template:Effect_list`,
  "wikipedia": `# Choline bitartrate
*Source: https://en.wikipedia.org/wiki/Choline_bitartrate*

Choline bitartrate is an organic compound with the chemical formula [(CH3)3NCH2CH2OH]+HOOC−CH(OH)−CH(OH)−COO−. It is a white crystalline powder with an acid taste. It is hygroscopic when exposed to air. Modern texts refer to the choline salt of the natural form of tartaric acid, that is, the salt called choline dextrobitartrate, choline (2R,3R)-bitartrate or choline L-(+)-bitartrate.

## Chemistry

Choline bitartrate is a choline salt of tartaric acid. Choline bitartrate contains quaternary ammonium cations ((2-hydroxyethyl)trimethylammonium [(CH3)3NCH2CH2OH]+) and bitartrate anions (HOOC−CH(OH)−CH(OH)−COO−). Quaternary ammonium cation is a cation in which all four hydrogen atoms of ammonium are replaced with organyl groups. In the choline cation, the four substituents of ammonium are three methyl groups (−CH3) and one 2-hydroxyethyl group (−CH2CH2OH). The bitartrate anion is chiral (there are left, right and meso forms of bitartrate, see tartaric acid).

## Production

Choline bitartrate can be produced by the chemical reaction of trimethylamine with ethylene oxide and water, followed by reaction with tartaric acid.
N(CH3)3 + CH2CH2O + H2O → [(CH3)3NCH2CH2OH]+OH−
[(CH3)3NCH2CH2OH]+OH− + C4H6O6 → [(CH3)3NCH2CH2OH]+C4H5O−6 + H2O

## Uses

Choline bitartrate is used as a dietary supplement, a food additive, a nutrient and as a lipotropic compound. It is also used as a medication against bipolar disorder and mania (see: choline). Certain conducted double-blind, placebo-controlled studies of the effects of choline bitartrate treatment against Alzheimer-type dementias suggest improvement in some areas of patients' cognitive performance.

## Safety

Choline bitartrate is flammable. When burned, choline bitartrate may release toxic gases, like carbon monoxide (CO), carbon dioxide (CO2) and nitrogen oxides (NO, NO2). May react violently with strong oxidizing agents.
The toxicity of this compound is similar to toxicity of choline itself, which is fairly low, and it is used as a dietary supplement. Oral LD50 value for a human is estimated to be 200 to 400 grams (as choline). Nevertheless, choline bitartrate can be harmful, if absorbed through skin. It may cause skin, eye and respiratory system irritation. May cause gastrointestinal system irritation as well. If swallowed in high doses, may cause dizziness, nausea, vomiting and diarrhea, and a rotten fish-like body smell resulting from the excretion of trimethylamine from the body (trimethylamine is a choline metabolite). There are reports of depression or increased symptoms of it in patients using high doses of choline bitartrate.  When choline bitartrate is used appropriately, hazardous effects are unlikely to occur.

== References ==
`,
};
